PCRX Pacira Biosciences Inc.

Pacira BioSciences to Present at the 2020 BMO Prescriptions for Success Healthcare Conference

Pacira BioSciences to Present at the 2020 BMO Prescriptions for Success Healthcare Conference

PARSIPPANY, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: PCRX) today announced that it will present at the 2020 BMO Prescriptions for Success Healthcare Conference at 10:00 AM ET on Tuesday, June 23, 2020. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at . A replay of the webcast will also be available for two weeks following the event.

About Pacira

Pacira BioSciences, Inc. (NASDAQ: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.  In April 2019, the company acquired the iovera⁰ system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit .

 

Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
EN
16/06/2020

Underlying

PCRXPacira Biosciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacira Biosciences Inc.

Free Trial
PCRX Pacira Bioscien...

Pacira Biosciences Inc: 2 directors

Two Directors at Pacira Biosciences Inc sold 19,954 shares at between 26.210USD and 26.240USD. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...

PCRX PACIRA BIOSCIENCES INC.
06/06/25 June 6, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on June 3, 2025 to 19 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the a...

June 5, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Presents New Data on the Effects of Clinical Immuno...

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee -- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at the ASGCT Annual Meeting -- BRISBANE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to t...

May 15, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Hea...

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21st at 8:30AM ET.2025 Jefferies Global Healthcare Conference on Wednesday, June 4th at 8:45AM ET. ...

May 14, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Reports First Quarter 2025 Financial Results

Pacira BioSciences Reports First Quarter 2025 Financial Results -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2025. First Quarter 2025 Financial Highlights Total revenues of $168.9 millionNet product sales of $136.5 million for EXPAREL, $23.3 million for ZILRETTA, and $5.1 million for iovera°Net income of $4.8 million, ...

May 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch